
    
      The objective of this study was to assess the single dose bioequivalence of Roxane's
      Ropinirole Tablets, 0.25 mg to ReQuip Tablets, 0.25 mg (GlaxoSmithKline) under fasting
      conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence cross-over
      design.
    
  